

12. (amended) The method of Claim 9, wherein the fumonisin analog is administered in an amount between 5 and 500 mg.

13. (amended) The method of Claim 9, wherein the fumonisin analog is administered in an amount between 25 and 75 mg.

14. (amended) The method of Claim 9, wherein X is CH_2OH or an ester thereof.

C2 15. (amended) The method of Claim 9, wherein the fumonisin analog has a 2-amino-3,5-diol head group.

16. (amended) The method of Claim 9, wherein the fumonisin analog is Fumonisin B₁.

C3 17. (amended) The method of Claim 9, wherein the fumonisin analog is Fumonisin B₂.

Please add the following claims:

47. (new) The method of Claim 9, wherein the neoplastic condition is esophageal cancer.

48. (new) The method of Claim 9, wherein the subject is a human.

49. (new) The method of Claim 9, wherein V is hydroxyl.

C4 50. (new) The method of Claim 9, wherein V is hydrogen and Y is hydrogen.

51. (new) The method of Claim 9, wherein V is hydroxyl and Y is hydrogen.

52. (new) The method of Claims 50 or 51, wherein X is methyl.